Bristol Myers buys Orum's blood cancer therapy for up to $180 mln

Reuters
2023.11.06 12:41
portai
I'm PortAI, I can summarize articles.

Nov 6 (Reuters) - Bristol Myers Squibbhas acquired Orum Therapeutics’ experimental therapy to treat a type of blood cancer for a total value of up to $180 million, the privately held company said on Monday.

Nov 6 (Reuters) - Bristol Myers Squibb (BMY.N) has acquired Orum Therapeutics’ experimental therapy to treat a type of blood cancer for a total value of up to $180 million, the privately held company said on Monday.

The therapy, ORM-6151, which helps degrade a specific protein hard to treat previously, has received the U.S. Food and Drug Administration’s (FDA) clearance for an early stage study.

The deal includes an upfront payment of $100 million and milestone payments, Orum said, without disclosing further details.

Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.